Managing Blood Clotting Issues in Advanced Prostate Cancer
Author Information
Author(s): Muacevic Alexander, Adler John R, Zheng Jie, Ibezue Chidera, Nguyen Nghi, Cai Qi, Qin Qian, Wang Jue
Primary Institution: University of Texas Southwestern Medical Center
Hypothesis
Can Lutetium-177 effectively manage disseminated intravascular coagulation in metastatic castrate-resistant prostate cancer?
Conclusion
Lutetium-177 successfully resolved a patient's life-threatening blood clotting issues associated with advanced prostate cancer.
Supporting Evidence
- The patient experienced a significant decrease in PSA levels after treatment.
- Laboratory results showed normalization of DIC parameters within two weeks post-treatment.
- Previous treatments for DIC in prostate cancer have included various chemotherapy agents.
Takeaway
This study shows that a special treatment can help patients with prostate cancer who have serious blood clotting problems.
Methodology
Case report detailing the management of a patient with recurrent DIC in advanced prostate cancer using Lutetium-177.
Limitations
Focus on a single patient limits generalizability; lack of comparative data and long-term follow-up.
Participant Demographics
75-year-old male with a history of prostate cancer and other medical conditions.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website